MedPath

成都米子生物医药科技有限公司

Ownership
-
Established
2022-03-30
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

9

NMPA:9

Drug Approvals

Bumetanide Injection

Product Name
布美他尼注射液
Approval Number
国药准字H20254456
Approval Date
Jun 3, 2025
NMPA

Nimodipine Injection

Product Name
尼莫地平注射液
Approval Number
国药准字H20254269
Approval Date
May 27, 2025
NMPA

Composite Potassium Hydrogen Phosphate Injection

Product Name
复合磷酸氢钾注射液
Approval Number
国药准字H20254120
Approval Date
May 13, 2025
NMPA

Lornoxicam for Injection

Product Name
注射用氯诺昔康
Approval Number
国药准字H20254046
Approval Date
Apr 30, 2025
NMPA

Pamidronate Disodium Injection

Product Name
帕米膦酸二钠注射液
Approval Number
国药准字H20253613
Approval Date
Mar 11, 2025
NMPA

Famotidine Injection

Product Name
法莫替丁注射液
Approval Number
国药准字H20253432
Approval Date
Feb 20, 2025
NMPA

Isoprenaline Hydrochloride Injection

Product Name
盐酸异丙肾上腺素注射液
Approval Number
国药准字H20249512
Approval Date
Dec 1, 2024
NMPA

Potassium Chloride Injection

Product Name
氯化钾注射液
Approval Number
国药准字H20249481
Approval Date
Dec 1, 2024
NMPA

Formoterol Fumarate Inhalation Solution

Product Name
富马酸福莫特罗吸入溶液
Approval Number
国药准字H20249179
Approval Date
Oct 22, 2024
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.